Join our community
TRT and PSA monitoring are closely linked when it comes to assessing prostate health during Testosterone Replacement Therapy. PSA (Prostate-Specific Antigen) is a blood marker commonly used as part of prostate assessment, and understanding how PSA may change during TRT can help put monitoring results into context.
Prostate health is also one of the most common concerns men have when considering TRT. For many years, testosterone was closely associated with fears about prostate growth and prostate cancer, but the relationship is more complicated than simply saying that testosterone “feeds” prostate cancer.
Current evidence does not establish that appropriately prescribed TRT causes prostate cancer. However, prostate health remains an important part of TRT monitoring, particularly through assessment of symptoms, PSA levels and changes over time. Any concerning results should be assessed by an appropriately qualified healthcare professional.
The key points to understand about testosterone, PSA and prostate monitoring.
The prostate is a gland located below the bladder and around the urethra. It contributes fluid to semen and commonly becomes larger as men get older.
Prostate tissue is androgen-sensitive, meaning hormones such as testosterone and dihydrotestosterone (DHT) interact with androgen receptors within the prostate.
This biological relationship contributed to the historic assumption that increasing testosterone would inevitably increase prostate cancer risk. Modern evidence suggests the relationship is more complex than a simple linear effect.
“TRT causes prostate cancer” is too simplistic. Current clinical guidance does not support treating testosterone therapy itself as a proven cause of prostate cancer. Prostate health should nevertheless be assessed before treatment and monitored appropriately during therapy.
PSA stands for Prostate-Specific Antigen. It is a protein produced by prostate tissue that can be measured with a blood test.
PSA can help identify when further prostate assessment may be useful, but it is not a cancer diagnosis by itself.
PSA may increase for several reasons, many of which are unrelated to prostate cancer.
PSA should be interpreted in context. Your age, previous PSA results, urinary symptoms, examination findings and other clinical factors may all influence how a result is interpreted.
PSA may increase after testosterone therapy is started in some men. A rise does not automatically mean that TRT has caused prostate cancer.
Establishing a PSA result before treatment gives the clinician a baseline against which future results can be compared. PSA is only one part of wider TRT blood monitoring, which we cover in our TRT Blood Testing Guide .
Prostate health and PSA should be considered before starting TRT where clinically appropriate. This provides a useful reference for future monitoring.
Changes over time can be more informative than one isolated value. An unexpectedly elevated PSA may sometimes be repeated before a decision is made about further investigation.
BSSM guidance states that a PSA increase greater than 1.4 ng/mL during any one-year period, or a sustained PSA velocity greater than 0.4 ng/mL per year over sequential measurements, warrants urological evaluation and closer surveillance.
Monitoring schedules vary according to age, baseline prostate risk, symptoms and the clinician responsible for treatment.
Prostate health should be considered before treatment. Depending on age and individual circumstances, this may include discussion of urinary symptoms, PSA testing and further prostate assessment.
BSSM guidance includes follow-up PSA assessment after treatment begins and ongoing monitoring thereafter. Your individual schedule should be determined by the clinician managing your TRT.
A rise does not automatically mean TRT must be stopped or that prostate cancer is present. Your clinician may repeat the test, assess possible causes, review the rate of change and decide whether urological assessment is appropriate.
Urinary symptoms are common as men get older and are often caused by benign prostate enlargement rather than cancer. Persistent or concerning symptoms should still be discussed with your GP.
These symptoms can have several causes, including benign prostate enlargement, but persistent or concerning changes are worth getting assessed.
Difficulty starting to urinate or needing to strain.
A weak or stop-start urinary stream.
Feeling that your bladder has not fully emptied.
Needing to urinate more frequently or urgently.
Regularly getting up during the night to urinate.
Blood in the urine.
Pain when urinating.
Being unable to urinate.
These symptoms do not automatically mean prostate cancer. Benign prostate enlargement is common, particularly as men get older. The important point is to have persistent or concerning symptoms assessed rather than assuming they are simply part of ageing or TRT.
This is an area where individual specialist advice is essential. Testosterone therapy should not be started or restarted simply on the basis of general information from the internet.
Active prostate cancer is an important contraindication or specialist consideration for testosterone therapy. In particular, locally advanced or metastatic prostate cancer requires specialist management rather than routine TRT prescribing.
The question of testosterone treatment following successful prostate cancer treatment is more complex and continues to be evaluated in clinical practice and research.
Decisions should take account of factors such as the type and stage of the original cancer, treatment received, current PSA status, time since treatment and overall clinical circumstances.
Where appropriate, the decision should involve a clinician with expertise in testosterone therapy together with the relevant urology or oncology team.
PSA can be temporarily influenced by factors unrelated to cancer. Following the preparation advice given by your GP or clinic can help reduce the chance of a misleading result.
For 48 hours before a PSA blood test, NHS guidance advises avoiding:
UKTRT provides general educational information and is not a medical service. We are not doctors. The information on this page should not be used as a substitute for individual medical advice, diagnosis, prostate assessment or treatment.
Do not start, stop or alter prescribed testosterone treatment because of a PSA result without discussing it with the clinician responsible for your care. A raised PSA does not automatically mean prostate cancer, but unexplained or significant changes should be appropriately assessed.
Further UK clinical information about PSA, prostate health and testosterone therapy is available from:
Current evidence does not establish that appropriately prescribed testosterone therapy causes prostate cancer. Prostate assessment and PSA monitoring nevertheless remain important before and during TRT.
PSA can rise after testosterone therapy begins in some men. A PSA increase does not automatically mean prostate cancer, but significant or persistent changes should be reviewed by the clinician responsible for your treatment.
PSA can rise because of benign prostate enlargement, inflammation, infection, recent activities affecting the prostate or prostate cancer. A high PSA therefore does not diagnose cancer by itself and should be interpreted in clinical context.
Prostate health and PSA should be considered before testosterone treatment where clinically appropriate. The exact assessment depends on factors such as age, symptoms, medical history and individual risk.
PSA is generally monitored after testosterone treatment begins and periodically thereafter. The exact schedule should be determined by your clinician according to your age, baseline PSA, symptoms and individual prostate risk.
No. Benign prostate enlargement is common and is not the same as prostate cancer. Persistent urinary symptoms should nevertheless be discussed with your GP.
Do not stop or alter prescribed testosterone based on a PSA result without discussing it with your clinician. They may repeat the test, investigate possible causes and decide whether urological assessment is appropriate.
This requires individual specialist assessment. Factors such as the original cancer, treatment received, current PSA, time since treatment and overall clinical circumstances need to be considered, often with input from urology or oncology.
